In the analysis of clinicopathological characteristics, MYL9 expression was closely related to the tumor TNM stage in bladder urothelial carcinoma, adrenocortical carcinoma, stomach adenocarcinoma, and thyroid carcinoma (Figure S1B). This evidence concerns the gene MYL9 and thyroid gland carcinoma.